Ionis Pharmaceuticals IONS Waylivra — Revenue
Discontinued — last reported Q2 '19
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 24, 2021, on SEC EDGAR. View the filing →
Questions, answered.
- What does waylivra — revenue mean?
- The net sales revenue generated from the commercial sale of the Waylivra pharmaceutical product.
- How do you interpret waylivra — revenue?
- An increase indicates growing market penetration or successful patient uptake for the therapy, while a decrease may signal competitive pressure, patent expiration, or changes in reimbursement coverage.
- How does waylivra — revenue compare across companies?
- Comparable to product-specific net revenue metrics reported by other biotechnology companies for individual commercialized rare disease therapies.